Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Moderna, Inc. has received an average analyst recommendation of "Hold", with five analysts rating the stock as a sell and three as a buy.
• The company's most recent earnings report showed a revenue decline of 41.1% compared to the same quarter last year, with an EPS of -$2.13.
• Institutional investors own approximately 75.33% of Moderna's stock, indicating significant interest from large financial entities.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) has been given an average recommendation of "Hold" by the twenty-three brokerages that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $41.8125.

Several brokerages recently weighed in on MRNA. Leerink Partners dropped their target price on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a report on Friday, August 22nd. Barclays dropped their target price on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Cowen initiated coverage on Moderna in a report on Sunday, July 13th. They set a "hold" rating for the company. Citigroup initiated coverage on Moderna in a report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price objective for the company. Finally, Bank of America dropped their price objective on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd.

Moderna Price Performance

Shares of MRNA stock opened at $27.92 on Thursday. The stock has a market capitalization of $10.90 billion, a PE ratio of -3.71 and a beta of 2.01. Moderna has a 1-year low of $23.15 and a 1-year high of $59.73. The business has a 50-day moving average of $25.98 and a 200 day moving average of $27.30.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Analysts anticipate that Moderna will post -9.61 EPS for the current year.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the business. Parkside Financial Bank & Trust lifted its holdings in Moderna by 19.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company's stock worth $65,000 after buying an additional 375 shares during the period. Probity Advisors Inc. lifted its holdings in Moderna by 2.6% in the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company's stock worth $411,000 after buying an additional 377 shares during the period. Deseret Mutual Benefit Administrators lifted its holdings in Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after buying an additional 392 shares during the period. Amalgamated Bank lifted its stake in shares of Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company's stock valued at $1,806,000 after purchasing an additional 408 shares during the period. Finally, Rothschild Investment LLC lifted its stake in shares of Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company's stock valued at $25,000 after purchasing an additional 446 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.